ASH 2024 Abstracts: What’s hot in MPN?

104

Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome

Alessia Campagna

09:45

241

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Marta Santaliestra

14:00 

242

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Francesca Palandri

14:15 

243

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Shivani Handa

14:30 

244

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Ayalew Tefferi

14:45 

245

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann

15:00

246

Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression

Orly Leiva

15:15

406

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival: an Analysis By the German Study Group for MPN (GSG-MPN)

Kirsi Manz

16:45

1790

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lucía Pérez-Lamas

17:30 (poster session)

1792

High Resolution Chest Computed Tomography Responses for a Cohort of Erdheima Chester Disease Patients with Pulmonary Involvement

Long Chang

17:30 (poster session)

481

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall

09:30 

482

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Haifa Kathrin Al-Ali

09:45

483

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas

10:00 

485

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Zi Yun Ng

10:30

655

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Firas El Chaer

16:30

656

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

Marina Kremyanskaya

16:45

659

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo

17:30

660

Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors

Johannes Luebke

17:45

3187

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Francesca Palandri

18:00 (poster session)

3178

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis

John O. Mascarenhas

18:00 (poster session)

871

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Alexandros Rampotas

14:45 

872

Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2V617F and MPN Prevention

Benjamin Rolles

15:00

997

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Claire Harrison

16:30 

998

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

John O. Mascarenhas

16:45 

999

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova

17:00 

1000

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas

17:15 

4559

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Aaron T. Gerds

18:00 (poster session)

LBA-4

Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Jihyun Song

07:30